NVO reports disappointing data from a phase III study on a novel obesity candidate, CagriSema. RHHBY buys rights to obesity candidate from Zealand Pharma.

Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this ...

With Roche's latest deal, a new contender enters the obesity space, which could threaten NVO and LLY's dominance in the ...

Roche partners with Zealand Pharma on obesity drug petrelintide, with a $5.3B deal including milestone payments and global ...

Roche's Xolair outperformed oral immunotherapy in a Phase 3 trial for food allergies, showing better tolerance and fewer ...

Roche RHHBY announced that it has entered into an ... Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous ...

Roche (RHHBY) is increasing its investment into the obesity space with an up to $5.3 billion deal with Danish drugmaker ...

First Horizon Advisors Inc. trimmed its holdings in shares of Roche Holding AG (OTCMKTS:RHHBY – Free Report) by 23.7% in the ...

Roche's rejuvenated drug portfolio and increased free cash flow signal a potential turnaround, but long-term charts and past performance warrant caution. Diagnostics business and AI integration ...

RHHBY has been the subject of a number of research ... Hancock Whitney Corp now owns 23,516 shares of the company’s stock valued at $820,000 after acquiring an additional 1,496 shares during ...